title: [Intravesical instillation chemotherapy of anticancer agents including cylocide: studies of prophylactic effects on the recurrence].
abstract: We studied the efficacy of intravesical instillation chemotherapy of anticancer agents including cylocide (CA) in the prevention of recurrence of bladder tumor after surgery. Totally 60 patients with superficial bladder tumor were enrolled into the study. The patients were randomly assigned to either one of three groups: CA 300 mg alone, CA 200 mg + mitomycin C (MMC) 10 mg, and CA 180 mg + adriamycin (ADM) 20 mg. These drugs were initially instilled once a day for one week, and then once a month until 2 years after surgery. Thereafter, the patients were followed up without instillation. The cumulative non-recurrence rates in the CA group was 76.5, 60.0 and 60.0% at 1, 2 and 3 years after the removal of bladder tumor, respectively, while that in the CA + MMC treated group 90.9, 75.3, and 75.3% and that in the CA + ADM treated group, 95.1, 82.9 and 82.9%, respectively. The recurrence rate in the CA, CA + MMC and CA + ADM treated group was 35.3, 27.3 and 19.0%, respectively, the recurrence indices 1.84, 1.07 and 0.74, and the mean times between recurrence 10.8, 16.5 and 18.0 months, respectively. Side effects were noted in 3 of the 17 cases (17.6%) in the CA group, in 3 of the 22 cases (13.6%) in the CA + MMC group and in 3 of the 21 cases (14.3%) in the CA + ADM treated group. These data show that intravesical CA instillation in combination with MMC or ADM is more effective for the prevention of recurrence than that of CA alone.
authors.affiliation: Department of Urology, Osaka City University Medical School.
authors.forename: R
authors.initials: R
authors.lastname: Yasumoto
authors.forename: M
authors.initials: M
authors.lastname: Asakawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshihara
authors.forename: W
authors.initials: W
authors.lastname: Sakamoto
authors.forename: T
authors.initials: T
authors.lastname: Iseki
authors.forename: T
authors.initials: T
authors.lastname: Nakatani
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Maekawa
authors.forename: S
authors.initials: S
authors.lastname: Nishio
mesh_terms: D000206:Actuarial Analysis; D000283:Administration, Intravesical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery
chemical_list: D008937:Mitomycins; D003561:Cytarabine; D016685:Mitomycin; D004317:Doxorubicin